Everest Medicines Limited (HKG:1952)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 12.42B |
| Revenue (ttm) | 1.90B |
| Net Income (ttm) | -331.36M |
| Shares Out | 351.34M |
| EPS (ttm) | -0.99 |
| PE Ratio | n/a |
| Forward PE | 58.66 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,569,695 |
| Average Volume | 3,128,082 |
| Open | 36.02 |
| Previous Close | 35.66 |
| Day's Range | 35.08 - 36.02 |
| 52-Week Range | 31.70 - 77.55 |
| Beta | 1.63 |
| RSI | 40.71 |
| Earnings Date | Mar 26, 2026 |
About Everest Medicines
Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. It pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam,... [Read more]
Financial Performance
In 2025, Everest Medicines's revenue was 1.71 billion, an increase of 141.51% compared to the previous year's 706.68 million. Losses were -297.77 million, -71.41% less than in 2024.
Financial numbers in CNY Financial StatementsNews
China biotech flow picks up as Everest seals US$250 million deal
China’s biopharmaceutical sector is seeing an uptick in deal-making, with sovereign wealth funds from Singapore and the United Arab Emirates joining Chinese state-backed investors to back next-generat...
Everest Medicines Advances With Major Licensing Deal, New Drug Application Approval
Everest Medicines Ltd. (1952.HK) last Thursday announced an exclusive licensing agreement to commercialize Micot's MT1013 for the treatment of secondary hyperparathyroidism (SHPT), worth up to 1.24 bi...
Everest Medicines Transcript: 44th Annual J.P. Morgan Healthcare Conference
The company is driving dual-engine growth through in-house R&D and in-licensing, with strong commercial execution in China. Nefecon leads sales growth, while new deals and innovative platforms in mRNA and BTK inhibitors support long-term expansion.
Everest Medicines Earnings Call Transcript: H1 2025
Strong revenue growth driven by Nefecon and expanding antibacterial portfolio, with supply constraints resolved and robust sales guidance for 2025–2026. VELSIPITY and SIBO advance toward regulatory milestones, while mRNA and CAR T platforms progress in clinical development.
Everest Medicines Earnings Call Transcript: H2 2024
Revenue surged 461% year-over-year to RMB 706.7 million, driven by Nefecon and XERAVA launches, with gross margin at 83% and non-IFRS net loss narrowing by 25%. Nefecon’s NRDL inclusion and strong pipeline progress position the company for continued growth.
AI-powered Cancer Vaccine In The Works
The company said the U.S. FDA has cleared the IND application for its self-developed EVM14, a tumor-associated antigen vaccine Key Takeaways: The FDA has cleared Everest Medicine's EVM14 cancer vaccin...
Everest Medicines Transcript: Status Update
Significant progress was reported on a proprietary mRNA platform, with the first patient dosed in a personalized cancer vaccine trial and IND submissions for an off-the-shelf TAA vaccine. The pipeline, including an in vivo CAR-T program, is advancing toward key 2024 milestones.
Everest Medicines Transcript: Study Update
EVER001, a novel reversible covalent BTK inhibitor, showed strong efficacy and safety in a phase I-B/II-A trial for primary membranous nephropathy, achieving high rates of immunological and clinical remission with favorable tolerability. Plans are underway for global phase II/III studies and broader renal indications.
Everest Medicines Earnings Call Transcript: H1 2024
Revenue surged 158% in H1 2024, driven by XERAVA and NEFECON launches, with gross margin at 83% and non-IFRS loss narrowing by 35%. The company is on track for RMB 700 million full-year revenue, advancing mRNA and renal pipelines, and maintaining a strong cash position.
Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update
Enrollment completed in PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis; revising guidance of topline data to first half 2025 PALIZADE Phase 2b clinical trial of ...
Everest Medicines Transcript: Goldman Sachs 45th Annual Global Healthcare Conference
Focused on renal and infectious diseases, leveraging in-licensing and internal R&D, with Nefecon’s launch targeting a large, underserved patient base. Commercial execution is strong in both renal and anti-infective portfolios, while mRNA innovation advances toward clinical milestones.